Inhaler Adherence in Severe Unstable Asthma (INCA-SUN)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02307669|
Recruitment Status : Recruiting
First Posted : December 4, 2014
Last Update Posted : August 16, 2019
The investigators hypothesize that aligning digital data on PEF and adherence with the patient's own clinical course achieves better asthma control and identifies risks for future loss of control, compared to current best practice. The study has an adherence optimisation phase, week 1-12 followed by a medication management phase, week 12 to week 32.
The investigators will compare two asthma education interventions, standard Guideline recommended practice and feedback from the individual's own INCA device, which assesses inhaler adherence and relates adherence with changes in PEF and symptom scores over time.
The study has two co-primary endpoints, one will be a comparison of the adherence to therapy and the other will be a comparison of the appropriateness of medication prescriptions between the two study groups.
|Condition or disease||Intervention/treatment||Phase|
|Asthma||Behavioral: INCA feedback Behavioral: Usual Care||Not Applicable|
The investigators hypothesize that aligning adherence, inhaler technique and digitally recorded PEF to inform patients and as the basis of prescribing decisions achieves better inhaler adherence and technique and also allows physicians to make appropriate prescribing decisions, compared to current best practice.
The investigators will compare two asthma education interventions, standard BTS/SIGN Guideline recommended practice and feedback from the individual's own INCA device, which assesses inhaler adherence and relates adherence with changes in PEF and symptom scores over time.
This education phase is followed by a medication optimisation phase (weeks 12-32) in which there are 3 cycles of medication optimisation guided by a digital script. The script either adjusts the medications following the GINA recommendation or uses the GINA recommendation but is supplemented with data on adherence and PEF that are recorded to digital, time-stamped, recording devices.
The aim of the study is to improve and maintain adherence to preventer therapy, so that medication and other costs as well as the quality of life, exacerbation rates are optimal.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||220 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Primary Purpose:||Supportive Care|
|Official Title:||A Study on Inhaler Adherence to Improve Poor Asthma Control|
|Study Start Date :||December 2015|
|Estimated Primary Completion Date :||January 1, 2020|
|Estimated Study Completion Date :||December 31, 2020|
Placebo Comparator: Routine inhaler adherence care
Normal Care group This management is based on the inhaler training recommendations of the BTS/SIGN group (http://www.brit-thoracic.org.uk/Portals/0/Guidelines/AsthmaGuidelines/sign101%20Jan%202012.pdf) and medication management of the GINA management strategy.
The core features of the "usual care" group are:
Behavioral: Usual Care
The core features of the "usual care" group are:
The patient's inhaler technique will be checked using a checklist, at each visit. If there are errors these will be corrected using teach-to-goal principals.
Adherence will be discussed and barriers to adherence addressed, using motivational interview techniques.
Written action plans for managing asthma, based on changes in PEF and symptoms will be given.
In follow up, medication changes in response to the above will be directed by these, as suggested by Guidelines.
Active Comparator: INCA feedback
Behavioral: INCA feedback
The study team have developed a device which is attached to inhalers that makes an audio recording of the inhaler being used. Analysis of this audio data provides objective evidence of the time of inhaler use, technique of use and the peak inspiratory flow the patient makes each time they use their inhaler. Our preliminary experiences with the information obtained from this device indicate that adherence is poor in patients with severe asthma due to any one the following issues poor time of use, errors in handling and low peak inspiratory flow rates.
- Mean rate of actual Adherence to preventer medication [ Time Frame: week 20 through 32 ]This study will focus on severe asthma patients, who remain uncontrolled and with frequent exacerbations requiring oral steroids and have an Asthma control test (ACT) score of <19 on enrollment.
- The between-group difference in the proportion of patients prescribed guideline appropriate medication at the end of the study. [ Time Frame: week 20 through 32 ]
The appropriateness of the prescribed therapy will be verified for each participant after study completion using all available adherence and PEF data.
Between-group differences will be further broken down by the following:
- The proportion of participants prescribed add-on therapy (e.g. Monoclonal antibody therapy)
- The proportion of participants whose ICS/LABA dose was increased
- The proportion of participants whose ICS/LABA dose was reduced
- Cost-effectiveness and economic evaluation of the INCA educational intervention [ Time Frame: First 8 weeks of the study and week 20 to 32 ]
An economic evaluation of national implementation of the INCA-SUN program will be provided. Data on the cost of the intervention (device, time taken to deliver, cost of training and salary cost of the trainer), medication costs, quality of life, exacerbations and other healthcare utilization and associated costs, such as unscheduled health care visits as well as work productivity losses will be collected alongside the 32-week study.
A cost-effectiveness and cost-utility analysis of the intervention compared to the control arm will be performed. Incremental cost-effectiveness ratios (or ICERS) will be calculated from the data, to estimate how much additional cost is required for an additional unit of benefit.
- Change in Asthma Control Test scores at week 32 [ Time Frame: Baseline to week 32 ]ACT scores will be obtained during the study visits.
- Change in PEF variability [ Time Frame: Baseline to week 32 ]Differences between the two study groups will be calculated
- Change in AQLQ [ Time Frame: Baseline to week 32 ]AQLQ scores will be obtained during the study visits.
- Exacerbations over study period [ Time Frame: Baseline to week 32 ]It is hypothesised that with active education, exacerbation frequency can be reduced.
- To compare the proportion of patients who were clinically stable [ Time Frame: First 8 weeks of the study and week 20 to 32 ]The proportion of patients who required no daily reliever use in the month prior to study end will be compared.
- Relationship of biomarkers with adherence [ Time Frame: Baseline to week 32 ]A comparison of changes in blood eosinophil's, periostin and Fractional Exhaled Nitric Oxide (FeNO) between the active and control groups will be made.The relationship between 7-day FeNO suppression and clinical and biomarker outcomes will be investigated.10. The relationship between changes in FeNO (characterised into FeNo>45ppb Or FeNO<45ppb) and adherence will also be investigated.
- The proportion of patients who are refractory to treatment [ Time Frame: First 8 weeks of the study and week 20 to 32 ]A comparison of the proportion of patients who are refractory, (defined as having actual adherence ≥80%, ≥1 exacerbation, PEF am/pm <80% and ACT ≤19) will be conducted.
- The proportion of patients who are non-adherent and remain uncontrolled [ Time Frame: First 8 weeks of the study and week 20 to 32 ]The proportion of patients who are non-adherent and remain uncontrolled, (i.e. Actual Adherence <80%, PEF am/pm <80% and ACT≤19) between the active and control groups will be compared.
- The proportion of patients with inhaler related side effects [ Time Frame: First 8 weeks of the study and week 20 to 32 ]The proportion of patients with inhaler related side effects including oral candidiasis between the active and control groups will be compared.
- Patient identified goal [ Time Frame: Baseline to week 32 ]Proportion of patients reaching stated clinical goal at week 12 and between that period and week 32.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02307669
|Contact: Elaine MacHale, RN MSCemail@example.com|
|Dublin, Ireland, 9|
|Contact: Elaine MacHale, RN MSc firstname.lastname@example.org|
|Contact: Lorna Lombard, RN email@example.com|
|Principal Investigator: Richard Costello, MD|
|Principal Investigator:||Richard w Costello, MD||RCSI|